We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

General Biologicals Corporation (GBC)

General Biologicals Corp. (GBC), founded in 1984, is the industry-leading in-vitro diagnostic device manufacturer in ... read more Featured Products: More products

Download Mobile App





General Biologicals Displays CLIA and Molecular Diagnostic Solutions at WHX Labs Dubai

By LabMedica International staff writers
Posted on 12 Feb 2026

At WHX Labs Dubai 2026, General Biologicals Corporation (GBC) is presenting its latest in vitro diagnostics (IVD) technologies and integrated laboratory solutions at Booth SA. More...

D50, February 10–13 at the Dubai World Trade Centre.

In molecular diagnostics, the company is demonstrating the AIO M160 fully automated system, which integrates nucleic acid extraction, amplification, and detection within a single platform. The system is designed to deliver a sample-to-result workflow, reducing manual intervention while improving operational efficiency. The compact system is built for efficiency, processing up to 16 samples simultaneously with a total turnaround time of under 2.5 hours. It features a high multiplexing capability with five qPCR channels, allowing for both qualitative and quantitative results from various sample types like whole blood, plasma, and tissue.

GBC is also showcasing its chemiluminescence immunoassay (CLIA) system, developed for laboratories of varying sizes. The platform includes the GBC CL i-120 CLIA System, an automated analyzer that optimizes workflows for protein and antibody detection. This technology is applied across a wide range of health targets, including thyroid function, tumor markers, and infectious disease screening.

Among the other featured technologies is the CellBio™ CTC circulating tumor cell detection platform, a non-invasive system designed to isolate circulating tumor cells (CTCs) from blood samples. The platform supports multi-level molecular analysis of DNA, RNA, and proteins, enabling applications in early cancer detection, therapy monitoring, and precision oncology research. The product lineup includes the CellBio™ a2000 for standard workflows and the CellBio™ FX10 for high-throughput laboratory environments. The platform preserves intact cell morphology, allowing for a wide range of downstream analyses including immunostaining, FISH, and NGS.

Live product demonstrations are being conducted at the booth, where attendees can learn more about the company’s technologies and discuss implementation and partnership opportunities.

Related Links:
General Biologicals Corporation


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
New
Portable POCT Blood Gas Analyzer
BD100
Automated Coagulation Analyzer
Hemolumi H6
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The platform analyzes cell-free DNA in blood, searching for minute amounts of tumor-derived fragments among background DNA (Image Credit: Adobe Stock)

Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings

Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.